Medical Science 2023 Paper II 50 marks Discuss

Q3

(a) Discuss in short the aetiology, clinical features, investigations and management of chronic renal failure. (5+5+5+5=20 marks) (b) (i) Write the causes of unconjugated hyperbilirubinemia in a newborn. (9 marks) (ii) What is the mechanism of action of phototherapy in the treatment of hyperbilirubinemia? (3 marks) (iii) What are the potential complications of the phototherapy? (3 marks) (9+3+3=15 marks) (c) (i) Mention the nail findings in psoriasis. (5 marks) (ii) Discuss the topical and systemic therapies in psoriasis. (10 marks) (5+10=15 marks)

हिंदी में प्रश्न पढ़ें

(a) चिरकारी वृक्क पात की हेतुकी, रोगलाक्षणिक विशेषताओं, जाँचों तथा प्रबंधन के बारे में संक्षेप में व्याख्या कीजिए। (5+5+5+5=20) (b) (i) नवजात में अयुग्मित अतिबिलिरुबिनरक्तता के कारण लिखिए। (9) (ii) अतिबिलिरुबिनरक्तता के उपचार में प्रकाश-चिकित्सा (फोटोथेरेपी) के कार्य करने की क्या विधि होती है? (3) (iii) फोटोथेरेपी की संभावित जटिलताएँ क्या-क्या हैं? (3) (9+3+3=15) (c) (i) सोरायसिस में नखों में होने वाले परिवर्तनों का उल्लेख कीजिए। (5) (ii) सोरायसिस में दी जाने वाली स्थलीय (टॉपिकल) एवं दैहिक चिकित्सा की व्याख्या कीजिए। (10) (5+10=15)

Evaluate your answer to this question → See all 2023 Medical Science questions

Directive word: Discuss

This question asks you to discuss. The directive word signals the depth of analysis expected, the structure of your answer, and the weight of evidence you must bring.

See our UPSC directive words guide for a full breakdown of how to respond to each command word.

How this answer will be evaluated

Approach

The directive 'discuss' demands a comprehensive, analytical treatment across all five sub-parts. Allocate approximately 40% of time/words to part (a) given its 20 marks, 30% to part (c) for its integrated therapeutic discussion, and 30% to part (b) with its mechanistic focus. Structure as: brief introduction → systematic coverage of (a) CRF with Indian CKD burden context → (b) neonatal jaundice with NICE/Indian Academy of Pediatrics alignment → (c) psoriasis with nail-specific details → concluding synthesis on chronic disease management.

Key points expected

  • Part (a): CRF aetiology—diabetic nephropathy, HTN, CGN, obstructive uropathy, CIN; CKD staging (GFR-based); uremic manifestations; dialysis modalities and transplant criteria
  • Part (b)(i): Unconjugated hyperbilirubinemia causes—physiological, breast milk jaundice, G6PD deficiency (common in India), ABO/Rh incompatibility, spherocytosis, hypothyroidism, Crigler-Najjar
  • Part (b)(ii-iii): Phototherapy mechanism—photoisomerization of unconjugated bilirubin to lumirubin and configurational isomers; complications—bronze baby syndrome, dehydration, retinal damage, skin rash, temperature instability
  • Part (c)(i): Nail findings in psoriasis—oil drop sign, pitting, onycholysis, subungual hyperkeratosis, splinter hemorrhages, nail bed salmon patch
  • Part (c)(ii): Topical therapy—corticosteroids, vitamin D analogues (calcipotriol), dithranol, coal tar; Systemic—methotrexate, cyclosporine, acitretin, biologics (anti-TNF, IL-17/23 inhibitors); PASI scoring relevance

Evaluation rubric

DimensionWeightMax marksExcellentAveragePoor
Concept correctness20%10Demonstrates precise pathophysiological accuracy: for (a) correctly distinguishes prerenal, renal, postrenal CRF with correct GFR cutoffs; for (b) accurately classifies hemolytic vs. hepatic causes of unconjugated hyperbilirubinemia and explains ZZ-configuration isomerization in phototherapy; for (c) correctly identifies IL-23/Th17 axis in psoriasis pathogenesisShows generally correct concepts with minor errors—e.g., confuses conjugated/unconjugated mechanisms, misstates GFR staging thresholds, or lists biologics without mechanism specificityFundamental conceptual errors—e.g., states phototherapy works on conjugated bilirubin, confuses CRF with AKI mechanisms, or describes nail psoriasis as fungal infection
Clinical correlation20%10Integrates Indian epidemiology and practice: cites rising CKD burden in India (ICMR data), G6PD deficiency prevalence in neonates, psoriasis impact on quality of life; correlates CRF symptoms with BUN/creatinine levels; links phototherapy indications to hour-specific bilirubin nomograms (Bhutani curves)Mentions clinical features without epidemiological context; lists symptoms of CRF or psoriasis without severity correlation; describes phototherapy use without gestational age considerationsNo clinical context—purely theoretical recitation; fails to mention Indian guidelines (IAP, RSSDI) or practical challenges like rural dialysis access
Diagram / pathway20%10Includes high-yield diagrams: CKD staging flowchart with GFR categories; bilirubin metabolism pathway showing conjugation defect sites; phototherapy mechanism schematic (4Z,15Z → 4Z,15E isomerization); nail psoriasis diagram labeling specific findings; therapeutic algorithm for psoriasisDescribes diagrams in text without actual sketching; or sketches basic CRF progression without staging details; mentions phototherapy without structural bilirubin changesNo diagrammatic representation despite clear opportunities; or incorrect diagrams (e.g., showing conjugated bilirubin pathway for unconjugated hyperbilirubinemia)
Differential / staging20%10Systematic differentials and staging: for (a) KDIGO CKD staging (G1-G5, A1-A3 albuminuria); for (b) distinguishes physiological vs. pathological jaundice by timing, rate of rise, family history; for (c) distinguishes plaque psoriasis from eczema, lichen planus, seborrheic dermatitis; mentions PASI/BSA scoringLists differentials without discriminating features; mentions CKD stages without GFR values; provides incomplete phototherapy indicationsNo staging system mentioned; fails to differentiate key conditions; or provides incorrect differentials (e.g., hepatitis for unconjugated hyperbilirubinemia)
Management / public-health angle20%10Comprehensive, evidence-based management with public health relevance: for (a) RRT initiation criteria, conservative care in resource-limited settings, PMNDP; for (b) exchange transfusion thresholds, IVIG for Rh/ABO disease, community-based phototherapy units; for (c) stepwise therapy per severity, biologic access programs, patient education on triggersLists treatments without sequencing or indication criteria; mentions dialysis/transplant without when-to-start; describes phototherapy without monitoring protocolsOutdated or dangerous management—e.g., phenobarbital as first-line for neonatal jaundice, systemic steroids for mild psoriasis, no mention of renal replacement timing

Practice this exact question

Write your answer, then get a detailed evaluation from our AI trained on UPSC's answer-writing standards. Free first evaluation — no signup needed to start.

Evaluate my answer →

More from Medical Science 2023 Paper II